Małgorzata Uhrynowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Małgorzata Uhrynowska has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Ewa Brojer
Zakład Immunologii Hematologicznej i Transfuzjologicznej Instytutu Hematologii i Transfuzjologii w Warszawie
13 shared publications - Katarzyna Guz
Department of Hematological and Transfusion Immunology Institute of Hematology and Transfusion Medicine Warsaw Poland
12 shared publications - Marzena Dębska
2nd Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland
9 shared publications - Agnieszka Orzińska
Department of Hematological and Transfusion Immunology Institute of Hematology and Transfusion Medicine Warsaw Poland
7 shared publications Anne Husebekk
5 shared publications- B. Zupańska
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
4 shared publications
Latest Publications
- Open Access
- 8 May 2019
- Published by VM Media Group sp. z o.o in Acta Haematologica Polonica
- Vol. 50 (1) , 21-24
Coexistence of hemoglobin Handsworth and alpha 3.7 kb deletion in Caucasian woman in Poland
Background: This report presents a case of an adult Polish women of Caucasian origin who was heterozygous for the nondeletional mutation: Hb Handsworth (HBA2 or HBA1: c.55G > C, p.Gly19Arg) and deletional (-α3.7) α-thalassemia mutation.Methods: The HbA2 and HbF levels were measured by microcolumn chromatography and alkaline denaturation procedure, respectively, while electrophoresis was used to detect pathological hemoglobin fraction. The β- and α-globin genotypes were determined by DNA sequencing, gap-polymerase chain reaction, α gene triplication and MLPA.Results: The HbA2 and HbF levels were normal, but hemoglobin electrophoresis on agarose gel alkaline pH showed a strong band migration in a position of hemoglobin S and faint bands in the neighborhood of band A on acid electrophoresis. Molecular analysis of the alpha globin cluster detected a point mutation at codon 19 in HBA2 (c.55G > C, p.Gl- y19Arg) and deletion -α3.7.Conclusions: Our compound heterozygosity does not produce severe clinical or hematological symptoms but it is important to say that in our part of Europe such cases do appear. Molecular analysis of the alpha globin cluster is required for correct diagnosis in patients with normal HbA2 levels. Compound heterozygosity was unmasked by molecular diagnosis only.
- 8 May 2019
- Published by VM Media Group sp. z o.o in Acta Haematologica Polonica
- Vol. 50 (1) , 21-24
Open AccessCoexistence of hemoglobin Handsworth and alpha 3.7 kb deletion in Caucasian woman in Poland
Background: This report presents a case of an adult Polish women of Caucasian origin who was heterozygous for the nondeletional mutation: Hb Handsworth (HBA2 or HBA1: c.55G > C, p.Gly19Arg) and deletional (-α3.7) α-thalassemia mutation.Methods: The HbA2 and HbF levels were measured by microcolumn chromatography and alkaline denaturation procedure, respectively, while electrophoresis was used to detect pathological hemoglobin fraction. The β- and α-globin genotypes were determined by DNA sequencing, gap-polymerase chain reaction, α gene triplication and MLPA.Results: The HbA2 and HbF levels were normal, but hemoglobin electrophoresis on agarose gel alkaline pH showed a strong band migration in a position of hemoglobin S and faint bands in the neighborhood of band A on acid electrophoresis. Molecular analysis of the alpha globin cluster detected a point mutation at codon 19 in HBA2 (c.55G > C, p.Gl- y19Arg) and deletion -α3.7.Conclusions: Our compound heterozygosity does not produce severe clinical or hematological symptoms but it is important to say that in our part of Europe such cases do appear. Molecular analysis of the alpha globin cluster is required for correct diagnosis in patients with normal HbA2 levels. Compound heterozygosity was unmasked by molecular diagnosis only.
- 8 January 2019
- Published by Wiley in Transfusion
- Vol. 59 (3) , 1102-1107
Prediction of fetal blood group and platelet antigens from maternal plasma using next‐generation sequencing
BACKGROUND: Fetuses whose mothers have produced antibodies to red blood cell (RBC) or platelet antigens are at risk of being affected by hemolytic disease or alloimmune thrombocytopenia, respectively, only if they inherit the incompatible antigen. Noninvasive diagnosis of the fetal antigen is employed for management of immunized pregnancies, but the specific detection of SNPs, encoding the majority of antigens, in maternal plasma is still a challenge. We applied targeted next‐generation sequencing (NGS) to predict the fetal antigen based on the detection of fetomaternal chimerism.METHODS AND MATERIALS: The DNA of 13 pregnant women (with anti‐K [3] anti‐k [1], anti‐Fya [1], anti‐D + C + Jka [1], anti‐D + E + K [1], anti‐HPA‐1a [1], anti‐HPA‐3b [1], anti‐HPA‐5b [1], and nonimmunized [3]) was sequenced using primers for regions encoding RhD, RhC, Rhc, RhE/e, K/k, Fya/b, Jka/b, MN, Ss, and HPA‐1, 2, 3, 5, 15, 4 X‐polymorphisms on the Ion Torrent Personal Genome Machine (PGM) System (Thermo Fisher Scientific, Inc., Waltham, MA, USA).RESULTS: NGS results were in agreement with the phenotype/genotype of women and their neonates (except for the unsuccessful detection of MN and RhC). NGS determined fetal allele chimerism for K, k, Fya, Fyb, Jka, Jkb, S, RhE (from 0.42% to 6.08%); RhD, Rhc (100%); HPA‐1a, −2b, −3a, 3b, −5b, −15a, 15b (from 0.23% to 4.11%). NGS revealed fetal chimerism for incompatible antigens (from 0.7% to 4.8%) in 7 immunized cases, excluded in 3 (with anti‐K, anti‐Fya, anti‐HPA‐3b).CONCLUSION: The designed NGS predicts the fetal RBC and platelet antigen status universally in cases with various clinically significant antibodies as well as providing confirmation of the presence of fetal DNA. However, some improvement of the unsuccessful primers is required.
- 8 January 2019
- Published by Wiley in Transfusion
- Vol. 59 (3) , 1102-1107
Prediction of fetal blood group and platelet antigens from maternal plasma using next‐generation sequencing
BACKGROUND: Fetuses whose mothers have produced antibodies to red blood cell (RBC) or platelet antigens are at risk of being affected by hemolytic disease or alloimmune thrombocytopenia, respectively, only if they inherit the incompatible antigen. Noninvasive diagnosis of the fetal antigen is employed for management of immunized pregnancies, but the specific detection of SNPs, encoding the majority of antigens, in maternal plasma is still a challenge. We applied targeted next‐generation sequencing (NGS) to predict the fetal antigen based on the detection of fetomaternal chimerism.METHODS AND MATERIALS: The DNA of 13 pregnant women (with anti‐K [3] anti‐k [1], anti‐Fya [1], anti‐D + C + Jka [1], anti‐D + E + K [1], anti‐HPA‐1a [1], anti‐HPA‐3b [1], anti‐HPA‐5b [1], and nonimmunized [3]) was sequenced using primers for regions encoding RhD, RhC, Rhc, RhE/e, K/k, Fya/b, Jka/b, MN, Ss, and HPA‐1, 2, 3, 5, 15, 4 X‐polymorphisms on the Ion Torrent Personal Genome Machine (PGM) System (Thermo Fisher Scientific, Inc., Waltham, MA, USA).RESULTS: NGS results were in agreement with the phenotype/genotype of women and their neonates (except for the unsuccessful detection of MN and RhC). NGS determined fetal allele chimerism for K, k, Fya, Fyb, Jka, Jkb, S, RhE (from 0.42% to 6.08%); RhD, Rhc (100%); HPA‐1a, −2b, −3a, 3b, −5b, −15a, 15b (from 0.23% to 4.11%). NGS revealed fetal chimerism for incompatible antigens (from 0.7% to 4.8%) in 7 immunized cases, excluded in 3 (with anti‐K, anti‐Fya, anti‐HPA‐3b).CONCLUSION: The designed NGS predicts the fetal RBC and platelet antigen status universally in cases with various clinically significant antibodies as well as providing confirmation of the presence of fetal DNA. However, some improvement of the unsuccessful primers is required.
- 27 September 2018
- Published by Wiley in Transfusion
- Vol. 58 (11) , 2705-2711
Noninvasive prenatal HPA‐1 typing in HPA‐1a negative pregnancies selected in the Polish PREVFNAIT screening program
BACKGROUND: Anti‐HPA‐1a alloantibodies in HPA‐1a negative mothers can lead to fetal/neonatal alloimmune thrombocytopenia (FNAIT). Noninvasive prenatal testing (NIPT) of HPA‐1a determines fetuses at risk and the course of maternal antenatal treatment. STUDY DESIGN AND METHODS: The aim was to develop and validate HPA‐1a NIPT by real‐time polymerase chain reaction (PCR) or next‐generation sequencing (NGS) for a high‐throughput screening setting. DNA from 328 plasma samples of 299 HPA‐1a negative pregnant women was examined for HPA‐1a by real‐time PCR and in two cases also by NGS (Ion Torrent). The results were compared with neonatal HPA‐1a genotyping in 281 cases. RESULTS: HPA‐1a NIPT was negative in 44 of 51 HPA‐1a negative fetuses, inconclusive in five, and false positive in two. In 228 of 229 HPA‐1a positive fetuses, the NIPT results were positive (mean threshold cycle 36.0 ± 1.7) and inconclusive in one. In 22 cases with HPA‐1a positive fetuses analyzed twice, the sensitivity of HPA‐1a detection was significantly higher at 28 weeks compared with 16 to 20 weeks. NGS efficiently detected the ITGB3 coding HPA‐1a/b (1% and 5% fetal HPA‐1a reads). CONCLUSION: Real‐time PCR is reliable to predict the fetal HPA‐1a positive genotype in a screening study, but false‐positive results are reported in 4%, with unnecessary prenatal treatment if anti‐HPA‐1a is detected.
- 27 September 2018
- Published by Wiley in Transfusion
- Vol. 58 (11) , 2705-2711
Noninvasive prenatal HPA‐1 typing in HPA‐1a negative pregnancies selected in the Polish PREVFNAIT screening program
BACKGROUND: Anti‐HPA‐1a alloantibodies in HPA‐1a negative mothers can lead to fetal/neonatal alloimmune thrombocytopenia (FNAIT). Noninvasive prenatal testing (NIPT) of HPA‐1a determines fetuses at risk and the course of maternal antenatal treatment. STUDY DESIGN AND METHODS: The aim was to develop and validate HPA‐1a NIPT by real‐time polymerase chain reaction (PCR) or next‐generation sequencing (NGS) for a high‐throughput screening setting. DNA from 328 plasma samples of 299 HPA‐1a negative pregnant women was examined for HPA‐1a by real‐time PCR and in two cases also by NGS (Ion Torrent). The results were compared with neonatal HPA‐1a genotyping in 281 cases. RESULTS: HPA‐1a NIPT was negative in 44 of 51 HPA‐1a negative fetuses, inconclusive in five, and false positive in two. In 228 of 229 HPA‐1a positive fetuses, the NIPT results were positive (mean threshold cycle 36.0 ± 1.7) and inconclusive in one. In 22 cases with HPA‐1a positive fetuses analyzed twice, the sensitivity of HPA‐1a detection was significantly higher at 28 weeks compared with 16 to 20 weeks. NGS efficiently detected the ITGB3 coding HPA‐1a/b (1% and 5% fetal HPA‐1a reads). CONCLUSION: Real‐time PCR is reliable to predict the fetal HPA‐1a positive genotype in a screening study, but false‐positive results are reported in 4%, with unnecessary prenatal treatment if anti‐HPA‐1a is detected.
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 14 (5) , 1041-1047
Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a
Introduction : Pregnant women negative for human platelet antigen 1 a (HPA-1a) are at risk of alloimmunization with fetal HPA-1a antigen inherited from the father, and their offspring may develop fetal and neonatal alloimmune thrombocytopenia (FNAIT). The aim of this study was to analyze the...
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 14 (5) , 1041-1047
Open AccessIdentification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a
Introduction : Pregnant women negative for human platelet antigen 1 a (HPA-1a) are at risk of alloimmunization with fetal HPA-1a antigen inherited from the father, and their offspring may develop fetal and neonatal alloimmune thrombocytopenia (FNAIT). The aim of this study was to analyze the...
- 3 February 2017
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 127 (3) , 190-194
Anti-platelet alloantibodies - recent advances in understanding their clinical relevance
Alloimmunization to human platelet antigens (HPAs) may occur either during pregnancy, when a HPA‑negative mother gives birth to a newborn who inherits HPAs from the father, or following blood transfusion or stem cell transplantation. Antiplatelet alloantibodies do not cause thrombocytopenia in a patient, but their detection must always be recorded in medical records because they may induce fetal and neonatal alloimmune thrombocytopenia in present and all subsequent pregnancies, platelet refractoriness, posttransfusion purpura, or prolonged thrombocytopenia with engraftment failure after stem cell transplantation. Passive transfer of platelet alloantibodies through transfused blood components may trigger thrombocytopenia and severe posttransfusion reactions in the recipient. In a Caucasian population, such clinical outcome of platelet alloimmunization is mostly due to anti‑HPA‑1a antibodies, less frequently to anti‑HPA‑5b, anti‑HPA‑1b, and others. Information on anti‑HPA alloantibodies is crucial for the prevention and treatment of their consequences.
- 3 February 2017
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 127 (3) , 190-194
Anti-platelet alloantibodies - recent advances in understanding their clinical relevance
Alloimmunization to human platelet antigens (HPAs) may occur either during pregnancy, when a HPA‑negative mother gives birth to a newborn who inherits HPAs from the father, or following blood transfusion or stem cell transplantation. Antiplatelet alloantibodies do not cause thrombocytopenia in a patient, but their detection must always be recorded in medical records because they may induce fetal and neonatal alloimmune thrombocytopenia in present and all subsequent pregnancies, platelet refractoriness, posttransfusion purpura, or prolonged thrombocytopenia with engraftment failure after stem cell transplantation. Passive transfer of platelet alloantibodies through transfused blood components may trigger thrombocytopenia and severe posttransfusion reactions in the recipient. In a Caucasian population, such clinical outcome of platelet alloimmunization is mostly due to anti‑HPA‑1a antibodies, less frequently to anti‑HPA‑5b, anti‑HPA‑1b, and others. Information on anti‑HPA alloantibodies is crucial for the prevention and treatment of their consequences.
- 1 October 2016
- Published by Walter de Gruyter GmbH in Acta Haematologica Polonica
- Vol. 47 (4) , 248-253
Analiza mutacji talasemii alfa u chorych diagnozowanych w Instytucie Hematologii i Transfuzjologii
- 1 October 2016
- Published by Walter de Gruyter GmbH in Acta Haematologica Polonica
- Vol. 47 (4) , 248-253
Analiza mutacji talasemii alfa u chorych diagnozowanych w Instytucie Hematologii i Transfuzjologii
- Open Access
- 12 November 2015
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 64 (4) , 279-290
Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare condition (1/1000–1/2000) that was granted orphan status by the European Medicines Agency in 2011. Clinical consequences of FNAIT, however, may be severe. A thrombocytopenic fetus or new-born is at risk of intracranial hemorrhage that may result in lifelong disability or death. Preventing such bleeding is thus vital and requires a solution. Anti-HPA1a antibodies are the most frequent cause of FNAIT in Caucasians. Its pathogenesis is similar to hemolytic disease of the newborn (HDN) due to anti-RhD antibodies, but is characterized by platelet destruction and is more often observed in the first pregnancy. In 75 % of these women, alloimmunization by HPA-1a antigens, however, occurs at delivery, which enables development of antibody-mediated immune suppression to prevent maternal immunization. As for HDN, the recurrence rate of FNAIT is high. For advancing diagnostic efforts and treatment, it is thereby crucial to understand the pathogenesis of FNAIT, including cellular immunity involvement. This review presents the current knowledge on FNAIT. Also described is a program for HPA-1a screening in identifying HPA-1a negative pregnant women at risk of immunization. This program is now performed at the Institute of Hematology and Transfusion Medicine in cooperation with the Department of Obstetrics and Gynecology of the Medical Centre of Postgraduate Education in Warsaw as well as the UiT The Arctic University of Norway.
- 12 November 2015
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 64 (4) , 279-290
Open AccessFetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare condition (1/1000–1/2000) that was granted orphan status by the European Medicines Agency in 2011. Clinical consequences of FNAIT, however, may be severe. A thrombocytopenic fetus or new-born is at risk of intracranial hemorrhage that may result in lifelong disability or death. Preventing such bleeding is thus vital and requires a solution. Anti-HPA1a antibodies are the most frequent cause of FNAIT in Caucasians. Its pathogenesis is similar to hemolytic disease of the newborn (HDN) due to anti-RhD antibodies, but is characterized by platelet destruction and is more often observed in the first pregnancy. In 75 % of these women, alloimmunization by HPA-1a antigens, however, occurs at delivery, which enables development of antibody-mediated immune suppression to prevent maternal immunization. As for HDN, the recurrence rate of FNAIT is high. For advancing diagnostic efforts and treatment, it is thereby crucial to understand the pathogenesis of FNAIT, including cellular immunity involvement. This review presents the current knowledge on FNAIT. Also described is a program for HPA-1a screening in identifying HPA-1a negative pregnant women at risk of immunization. This program is now performed at the Institute of Hematology and Transfusion Medicine in cooperation with the Department of Obstetrics and Gynecology of the Medical Centre of Postgraduate Education in Warsaw as well as the UiT The Arctic University of Norway.
- Open Access
- 1 November 2015
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 42 (6) , 361-364
14 Years of Polish Experience in Non-Invasive Prenatal Blood Group Diagnosis
Background: Blood cell antigens may cause maternal alloimmunization leading to fetal/newborn disorders. Non-invasive prenatal diagnostics (NIPD) of the blood group permits the determination of feto-maternal incompatibility. Aim: To evaluate 14 years of blood group NIPD at the Institute of Hematology and Transfusion Medicine (IHTM) in Warsaw. Methods: Plasma DNA from 536 RhD-negative, 24 Rhc-negative, 26 RhE-negative, 43 K-negative, and 42 HPA-1a-negative pregnant women was examined by real-time PCR to detect RHD, RHCE*c, RHCE*E, RHCE*C,KEL*01 and HPA*1A, respectively. We tested for CCR5, SRY or bi-allelic polymorphisms and quantified the total or fetal DNA. Results: The results of fetal antigen status prediction by NIPD in all but one case (false-positive result of KEL*01) were correct taking neonate serology as a reference. It was confirmed that all negative results of NIPD contained fetal DNA except for four cases where there was no difference between the parents' polymorphisms. Conclusions: A fetal genotype compatible with the mother was determined in 25% of all pregnancies tested at the IHTM for the fetal blood group. These cases were not at risk of disease, so it was possible to avoid invasive procedures.
- 1 November 2015
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 42 (6) , 361-364
Open Access14 Years of Polish Experience in Non-Invasive Prenatal Blood Group Diagnosis
Background: Blood cell antigens may cause maternal alloimmunization leading to fetal/newborn disorders. Non-invasive prenatal diagnostics (NIPD) of the blood group permits the determination of feto-maternal incompatibility. Aim: To evaluate 14 years of blood group NIPD at the Institute of Hematology and Transfusion Medicine (IHTM) in Warsaw. Methods: Plasma DNA from 536 RhD-negative, 24 Rhc-negative, 26 RhE-negative, 43 K-negative, and 42 HPA-1a-negative pregnant women was examined by real-time PCR to detect RHD, RHCE*c, RHCE*E, RHCE*C,KEL*01 and HPA*1A, respectively. We tested for CCR5, SRY or bi-allelic polymorphisms and quantified the total or fetal DNA. Results: The results of fetal antigen status prediction by NIPD in all but one case (false-positive result of KEL*01) were correct taking neonate serology as a reference. It was confirmed that all negative results of NIPD contained fetal DNA except for four cases where there was no difference between the parents' polymorphisms. Conclusions: A fetal genotype compatible with the mother was determined in 25% of all pregnancies tested at the IHTM for the fetal blood group. These cases were not at risk of disease, so it was possible to avoid invasive procedures.